Quantcast
Last updated on April 17, 2014 at 12:21 EDT

Latest Humanized antibody Stories

2013-01-07 12:27:46

ROCHESTER, N.Y., Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis. VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the second clinical trial for this investigational drug. Signaling cascades initiated by SEMA4D regulate...

2012-12-06 08:27:09

WALTHAM, Mass., Dec. 6, 2012 /PRNewswire/ -- NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. Preclinical studies of NKTT120, a humanized monoclonal antibody, showed its ability to generate a safe, rapid, specific and complete depletion of invariant Natural Killer T cells (iNKT cells) 24 hours post dosing,...

2012-11-11 16:20:29

BURLINGAME, Calif., Nov. 11, 2012 /PRNewswire/ -- Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (NYSE:SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the...

Humanized Mice May Aid In Arthritis Research
2012-10-04 14:47:55

Michael Harper for redOrbit.com — Your Universe Online Rheumatoid arthritis research has just had an advance as scientists from the Northwestern University Feinberg School of Medicine have finally found an animal which has the same response to the disease as people: Humanized mice. This discovery will improve arthritis research, giving scientists an accurate model with which to try new drugs and procedures in an effort to treat and cure the disease. The research team, lead by...

2012-09-19 02:29:40

SEATTLE, Sept. 19, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the National Institute of Mental Health (NIMH) awarded a grant to the Company for its proprietary antibody discovery (DTLacO) platform. With this approximately $700,000 NIMH award, Omeros will use its DTLacO platform to develop antibodies targeting orphan G protein-coupled receptors (GPCRs) that are associated with neurological disorders. Omeros' proprietary DTLacO technology is an efficient ex...

2012-09-14 02:23:45

TEL HAI, Israel, September 14, 2012 /PRNewswire/ -- cCAM Biotherapeutics [http://www.ccam-bio.com ], a biopharmaceutical company focused on the discovery and development of novel immunomodulatory drugs for cancer, announced today the completion of its Series A financing . The round was led by Arkin Holdings and included participation from OrbiMed's Israel Partners, Pontifax and F.Hoffmann La Roche. ROG.VX. cCAM Biotherapeutics is a pre-clinical stage company developing...

2012-08-15 18:20:41

BURLINGAME, Calif., Aug. 15, 2012 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China. Upon approval of the IND, APX001/SSS07 will be studied in clinical trials for the treatment of...

2012-05-16 06:26:53

NEW YORK, May 16, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced it has filed three new patent applications with the United States Patent and Trademark Office (USPTO), which expand the Company's immunotherapy pipeline. (Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO)...

2012-04-10 02:26:17

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch(TM) technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated...

2012-04-02 23:01:33

The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom´s prestigious Medical Research Council, have reached an agreement to collaborate on the development of monoclonal antibodies that can be commercialized as drugs to control infection and treat diseases. New York (PRWEB) April 02, 2012 The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom´s prestigious...